CD8A and neoplasm: The combination of 2 mAbs significantly increased CD8+ and CD4+ cells and decreased immunosuppressive CD4+FoxP3+ Tregs and CD11b+Gr-1+ Myeloid Suppressor Cells (MDSC) at tumor sites.